Voyager CEO sells shares to cover RSU taxes

Voyager Therapeutics, Inc. President and CEO Alfred Sandrock reported an open-market sale of 11,511 shares of common stock at a weighted average price of $3.87 per share.

Rhea-AI Filing Summary

Voyager Therapeutics, Inc. President and CEO Alfred Sandrock reported an open-market sale of 11,511 shares of common stock at a weighted average price of $3.87 per share. The transaction occurred under a durable automatic sale instruction to cover tax withholding on restricted stock units that vested on April 1, 2026.

The filing notes the sale was not a discretionary trade by Sandrock. Following this sell-to-cover transaction, he directly holds 472,549 shares of Voyager Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 11,511 shares

Net Sell 1 txn

Insider Sandrock Alfred

Role President and CEO

Sold 11,511 shs ($45K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,511	$3.87	$45K

Holdings After Transaction: Common Stock — 472,549 shares (Direct)

Footnotes (2)

1. F1. Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2026. The sales do not represent a discretionary trade by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $3.95, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Key Figures

Shares sold: 11,511 shares Weighted average sale price: $3.87 per share Sale price range: $3.81–$3.95 per share +3 more

6 metrics

Shares sold 11,511 shares Open-market sale on April 2, 2026

Weighted average sale price $3.87 per share Common Stock sale

Sale price range $3.81–$3.95 per share Multiple transactions within this range

Shares held after transaction 472,549 shares Direct ownership following sale

RSU vesting date April 1, 2026 RSUs triggering tax sell-to-cover

Transaction date April 2, 2026 Date of reported open-market sale

Key Terms

durable automatic sale instruction, sell-to-cover, restricted stock units, weighted average price

4 terms

durable automatic sale instruction financial

"sold, pursuant to a durable automatic sale instruction adopted by the reporting person"

sell-to-cover financial

"effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

restricted stock units financial

"in connection with the vesting of restricted stock units on April 1, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Voyager Therapeutics (VYGR) report for its CEO?

Voyager Therapeutics reported that CEO Alfred Sandrock sold 11,511 common shares at a weighted average price of $3.87. This was an automatic sell-to-cover transaction tied to restricted stock units vesting on April 1, 2026, rather than a discretionary stock sale.

Why did Voyager Therapeutics (VYGR) CEO Alfred Sandrock sell 11,511 shares?

The 11,511-share sale by CEO Alfred Sandrock was executed to satisfy tax withholding obligations from vesting restricted stock units. It occurred under a durable automatic sale instruction, meaning the transaction was pre-arranged and not a discretionary market-timing decision by the executive.

At what price were the Voyager Therapeutics (VYGR) shares sold in this Form 4?

The Form 4 reports a weighted average sale price of $3.87 per share. The shares were sold in multiple transactions within a range of $3.81 to $3.95. The company offers to provide exact share counts at each price level upon request to investors or regulators.

How many Voyager Therapeutics (VYGR) shares does the CEO hold after this tax-related sale?

After selling 11,511 shares, CEO Alfred Sandrock directly holds 472,549 Voyager Therapeutics common shares. This shows the transaction represented a small portion of his total position and was linked to tax withholding on recently vested restricted stock units, not a full position change.

Was the Voyager Therapeutics (VYGR) CEO’s share sale a discretionary trade?

The filing states the CEO’s sale was not discretionary. It was executed under a durable automatic sale instruction adopted earlier, specifically to effect a sell-to-cover election for tax withholding on restricted stock units that vested on April 1, 2026, rather than an opportunistic market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 05:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandrock Alfred

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/02/2026		S(1)		11,511(1)	D	$3.87(2)	472,549	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2026. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $3.95, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

	/s/ Gregory L. Shiferman, as Attorney-in-Fact for Alfred Sandrock	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)